08:31 AM EDT, 09/17/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Tuesday that it has completed price negotiations with the pan-Canadian Pharmaceutical Alliance for Orladeyo, BioCryst's treatment for hereditary angioedema.

The negotiation process concluded on Thursday last week, according to the pCPA's website.

BioCryst said it now expects to partner with the individual public drug plans of provinces and territories to add Orladeyo to public formularies.

Price: 7.85, Change: -0.06, Percent Change: -0.76